1. Home
  2. CX vs JAZZ Comparison

CX vs JAZZ Comparison

Compare CX & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cemex S.A.B. de C.V. Sponsored ADR

CX

Cemex S.A.B. de C.V. Sponsored ADR

N/A

Current Price

$13.09

Market Cap

17.7B

Sector

Industrials

ML Signal

N/A

Logo Jazz Pharmaceuticals plc (Ireland)

JAZZ

Jazz Pharmaceuticals plc (Ireland)

N/A

Current Price

$242.26

Market Cap

15.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CX
JAZZ
Founded
1906
2003
Country
Mexico
Ireland
Employees
39462
N/A
Industry
Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.7B
15.6B
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
CX
JAZZ
Price
$13.09
$242.26
Analyst Decision
Buy
Strong Buy
Analyst Count
8
14
Target Price
$12.21
$217.57
AVG Volume (30 Days)
4.6M
789.8K
Earning Date
04-23-2026
05-05-2026
Dividend Yield
0.74%
N/A
EPS Growth
N/A
N/A
EPS
N/A
4.43
Revenue
N/A
$1,618,693,000.00
Revenue This Year
$8.28
$6.22
Revenue Next Year
$4.34
$7.68
P/E Ratio
$19.03
$54.80
Revenue Growth
N/A
N/A
52 Week Low
$7.64
$105.00
52 Week High
$13.67
$250.49

Technical Indicators

Market Signals
Indicator
CX
JAZZ
Relative Strength Index (RSI) 57.14 58.15
Support Level $11.64 $222.49
Resistance Level $13.39 $250.49
Average True Range (ATR) 0.31 6.94
MACD 0.10 -0.31
Stochastic Oscillator 75.72 64.23

Price Performance

Historical Comparison
CX
JAZZ

About CX Cemex S.A.B. de C.V. Sponsored ADR

Cemex SAB de CV is a ready-mix concrete company that mainly engaged in activities that are oriented to the construction industry, mainly through the production, marketing, sale, and distribution of cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and also provide related services and reliable construction-related services to customers and communities and maintain business relationships in more than 60 countries throughout the world. The company operates in different parts of the world, with operations in Mexico, the United States, the EMEA region and the SCA&C region.

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Share on Social Networks: